Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

A previous version of this report failed to reflect that the scientific name tirzepatide refers to Zepbound. It has been corrected. A study of two blockbuster weight-loss drugs showed that users ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

ABC News chief medical correspondent Dr. Tara Narula breaks down what to know about a new study that says Zepbound may be ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...